Pulmonary Drug Delivery Market in India

Pulmonary Drug Delivery in India Trends and Forecast

The future of the pulmonary drug delivery market in India looks promising with opportunities in the hospitals & clinic and home care markets. The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2031 with a CAGR of 2.5% from 2025 to 2031. The pulmonary drug delivery market in India is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising prevalence of respiratory diseases, growing awareness of the benefits of pulmonary drug delivery, and the increasing demand for home-based healthcare services.

• Lucintel forecasts that, within the application category, chronic obstructive pulmonary disease (COPD) segment will remain the largest segment over the forecast period due to the increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

• Within the end use category, hospitals & clinics will remain the larger segment due to the growing number of hospital pharmacies across the globe.

Emerging Trends in the Pulmonary Drug Delivery Market in India

India’s pulmonary drug delivery market is evolving rapidly due to rising cases of respiratory diseases like asthma, COPD, and increasing awareness about advanced treatment options. Technological innovations, particularly in drug delivery devices, have enhanced the quality of life for patients. With a large and growing population suffering from respiratory issues, there is an increasing demand for efficient, easy-to-use pulmonary drug delivery devices. These trends indicate a promising future for the industry, driven by technological advancements and an improving healthcare infrastructure.

• Rise in Respiratory Disease Awareness: The increasing prevalence of respiratory diseases in India, such as asthma and COPD, has led to greater awareness of pulmonary drug delivery options. The growth in healthcare infrastructure, coupled with awareness campaigns, has boosted demand for devices like inhalers and nebulizers. This trend is expected to drive market growth, as more individuals seek timely treatment for chronic respiratory conditions. Increased awareness also reduces stigma around using drug delivery devices, improving patient adherence and leading to better outcomes for individuals managing respiratory diseases in India.

• Growth in Self-Management Technologies: Self-management of chronic respiratory diseases is becoming more prevalent in India, with patients relying on advanced inhalers and nebulizers that offer better control over their conditions. The trend toward self-management has led to a surge in the use of portable and easy-to-use pulmonary drug delivery devices. These technologies enable patients to administer treatments at home, reducing hospital visits and improving overall convenience. As India’s healthcare system becomes more focused on outpatient care, this trend is expected to expand, empowering patients to manage their conditions more effectively.

• Technological Advancements in Inhaler Devices: Technological advancements in inhaler devices are reshaping India’s pulmonary drug delivery market. Smart inhalers, which integrate IoT for monitoring usage, are gaining popularity. These devices provide real-time data to healthcare providers, enabling personalized treatment plans. They also track medication adherence and inhalation technique, which is crucial for effective treatment. The rise of these devices allows better disease management, and their growth could significantly improve patient outcomes in India, especially in managing chronic conditions like asthma and COPD.

• Expanding Availability of Combination Inhalers: Combination inhalers, which combine multiple therapeutic agents into one device, are increasingly available in India. These inhalers offer a convenient treatment option for individuals with chronic conditions like asthma and COPD, simplifying complex regimens. The availability of combination inhalers ensures better adherence by reducing the number of devices required, making it easier for patients to follow their treatment plans. This trend is driving market growth, as more individuals opt for combination therapies that offer enhanced effectiveness in managing respiratory diseases. The Indian government is taking steps to improve the healthcare system, with increased focus on respiratory diseases due to their growing burden. Initiatives such as subsidies for medication and pulmonary drug delivery devices, along with awareness programs, are expected to promote the use of advanced drug delivery systems. Furthermore, the government is collaborating with private sector players to improve accessibility to these devices, ensuring that they reach even rural and underserved populations. This will lead to wider adoption of pulmonary drug delivery technologies across India.

Recent Developments in the Pulmonary Drug Delivery Market in India

India’s pulmonary drug delivery market has been evolving with notable developments aimed at addressing the country’s rising burden of respiratory diseases. There has been an increase in the availability of advanced inhalers, the growth of self-management technologies, and greater government support for respiratory health. The availability of combination inhalers and technological advancements in inhaler devices are shaping the market, leading to better patient adherence and improved outcomes. These changes reflect a shift toward more patient-centered care in India, making it easier to manage chronic respiratory conditions.

• Availability of Advanced Inhalers: The market in India is seeing a rise in the availability of advanced inhalers with improved delivery mechanisms. Devices like metered-dose inhalers and dry powder inhalers (DPIs) have become more accessible to patients, offering better control over medication delivery. These devices ensure that drugs reach the lungs more efficiently, enhancing therapeutic outcomes. The widespread use of advanced inhalers is crucial in addressing the country’s rising prevalence of asthma and COPD, ensuring that patients receive optimal care for managing their conditions.

• Integration of IoT with Inhaler Devices: Smart inhalers integrated with IoT technology are revolutionizing the pulmonary drug delivery market in India. These devices offer features like usage tracking, inhalation technique monitoring, and real-time data sharing with healthcare providers. This allows for personalized treatment regimens and better patient engagement. With IoT integration, healthcare providers can remotely monitor patient adherence and make timely adjustments, ultimately improving disease management and preventing exacerbations of respiratory conditions. This trend is expected to significantly boost the efficacy of treatment in India.

• Combination Inhalers for Enhanced Efficacy: The increasing availability of combination inhalers is reshaping treatment protocols for chronic respiratory diseases in India. These inhalers combine multiple drugs, such as bronchodilators and corticosteroids, into a single device, improving patient compliance. The trend is particularly important in treating asthma and COPD, where adherence to complex medication regimens can be challenging. The introduction of combination inhalers simplifies treatment, providing more efficient symptom control and reducing the number of devices needed by patients. This is helping improve the overall management of respiratory diseases in India.

• Government Initiatives to Promote Respiratory Health: India’s government has launched various initiatives to tackle the rising burden of respiratory diseases. Through subsidized healthcare programs and increased funding for respiratory health, the government is making pulmonary drug delivery devices more accessible to the population. In addition, public health campaigns are raising awareness about chronic respiratory diseases and the importance of early diagnosis and treatment. These measures are expected to drive market growth, particularly in underserved areas, improving access to advanced drug delivery technologies for a larger segment of the population.

• Rise in Home-Based Treatment Solutions: As India’s healthcare system shifts toward outpatient care, home-based treatment solutions for chronic respiratory diseases are becoming more common. Devices like portable nebulizers and inhalers are increasingly being used by patients to manage their conditions from home, reducing hospital visits. The growing availability of these devices has made it easier for patients to adhere to treatment plans, improving quality of life. This shift toward home-based solutions is expected to play a significant role in the expansion of the pulmonary drug delivery market in India. The pulmonary drug delivery market in India is rapidly evolving, driven by advances in inhaler technology, increased availability of combination therapies, and a growing emphasis on patient-centered care. Government initiatives and the rise of home-based treatment options are further reshaping the market, ensuring wider access to essential respiratory care. These trends point to a promising future for the market, with improved patient outcomes and a more efficient healthcare system. The focus on convenience, efficiency, and accessibility is setting the stage for sustained growth in India’s pulmonary drug delivery sector.

Strategic Growth Opportunities for Pulmonary Drug Delivery Market in India

India’s pulmonary drug delivery market is experiencing significant expansion due to increasing rates of respiratory diseases like asthma, COPD, and bronchitis. With a growing aging population and rising air pollution levels, the demand for innovative pulmonary drug delivery solutions has increased. The country’s vast healthcare infrastructure, coupled with an expanding middle class, offers substantial growth opportunities in this market. As India’s healthcare system evolves, these opportunities are poised to drive advancements in drug delivery technologies and improve patient outcomes across the country.

• Expansion of combination therapies: Combination therapies in pulmonary drug delivery are gaining traction in India as they simplify treatment regimens. These therapies, which combine multiple drugs like bronchodilators and corticosteroids in a single inhaler, improve patient adherence and treatment efficiency. In India, where managing chronic diseases is a growing challenge, combination therapies offer an effective solution to improve patient compliance and reduce healthcare costs. The increased focus on managing asthma and COPD will lead to higher demand for these advanced drug delivery systems in the country.

• Rise in biologic therapies: Biologic therapies, particularly monoclonal antibodies, are revolutionizing the treatment of severe asthma and other respiratory diseases in India. These therapies target specific immune pathways, providing more effective treatments for patients who are unresponsive to traditional therapies. As biologics gain regulatory approval and are integrated into India’s healthcare system, demand for specialized inhalers capable of delivering biologics will increase. The growing healthcare infrastructure and access to advanced treatments are expected to drive the adoption of biologic therapies in the Indian market.

• Development of smart inhalers: Smart inhalers, which incorporate digital technologies such as sensors and mobile apps, are expected to significantly transform the pulmonary drug delivery market in India. These devices track medication usage, monitor patient adherence, and send reminders, enhancing treatment efficacy. Given the challenges of managing chronic respiratory conditions like asthma and COPD in India, smart inhalers offer a powerful solution for improving patient compliance and reducing hospitalizations. The rise of mobile health technologies in India presents a unique opportunity for the widespread adoption of these devices.

• Personalized medicine approaches: Personalized medicine, which tailors treatments to an individual’s genetic makeup, is a growing trend in the pulmonary drug delivery market in India. By using genetic and phenotypic data, physicians can prescribe more effective treatments for respiratory conditions. This approach enhances the efficacy of treatments and minimizes side effects, improving patient outcomes. The demand for devices that can deliver personalized therapies is expected to increase, as more patients in India seek customized solutions to manage chronic pulmonary diseases.

• Government support and healthcare funding: The Indian government has been increasingly focused on improving healthcare access and affordability, particularly for respiratory diseases. With the implementation of schemes like Ayushman Bharat, which aims to provide health coverage to low-income families, there is an expanding market for affordable pulmonary drug delivery devices. The government’s commitment to enhancing healthcare infrastructure and increasing funding for disease prevention will drive growth in the pulmonary drug delivery market. As access to healthcare improves, the adoption of advanced inhalers and therapies will rise across India. The pulmonary drug delivery market in India is set for substantial growth driven by increasing prevalence of respiratory diseases, technological advancements, and government support. Key opportunities lie in the expansion of combination therapies, biologic treatments, and personalized medicine. With the adoption of smart inhalers and continued healthcare improvements, India’s market is expected to witness rapid advancements in drug delivery technologies. These factors will contribute to better management of pulmonary diseases, enhancing patient outcomes and market growth.

Pulmonary Drug Delivery Market in India Driver and Challenges

The pulmonary drug delivery market in India is influenced by a variety of factors, including technological, economic, and regulatory drivers, as well as several challenges. Key growth drivers include the increasing prevalence of respiratory diseases, the rise of digital health technologies, and greater government support for healthcare initiatives. However, challenges such as high treatment costs, limited access in rural areas, and regulatory hurdles also need to be addressed. These drivers and challenges will shape the future of the market in India. The factors responsible for driving the pulmonary drug delivery market in India include:

• Rising prevalence of respiratory diseases: The rising prevalence of respiratory diseases, particularly asthma, COPD, and bronchitis, is a major driver of the pulmonary drug delivery market in India. With air pollution levels in major cities and an aging population, the demand for advanced pulmonary treatments continues to grow. This leads to an increased need for drug delivery devices like inhalers and nebulizers that can provide effective and efficient medication. As more people are diagnosed with chronic respiratory conditions, the market for these devices will continue to expand in India.

• Technological advancements in inhaler devices: Technological advancements in inhaler devices, such as the development of smart inhalers and combination therapy devices, are boosting the market. These devices improve the precision and efficiency of drug delivery, enhancing patient adherence to prescribed therapies. In India, where managing chronic respiratory diseases is a significant challenge, these innovations present a promising solution. The increased availability of digital health tools and mobile applications further supports the adoption of these advanced devices, driving market growth and improving treatment outcomes.

• Increased healthcare funding and government initiatives: The Indian government has been actively investing in healthcare through initiatives like Ayushman Bharat and the National Health Mission. These initiatives aim to improve access to healthcare, particularly for low-income populations. As healthcare spending increases, there will be a greater focus on providing affordable pulmonary treatments, including advanced inhaler devices. Government funding for disease prevention and management will facilitate market growth by enabling wider access to advanced therapies and devices, especially in rural areas where healthcare infrastructure is limited. Challenges in the pulmonary drug delivery market in India are:

• Growing awareness and patient education: Growing awareness of respiratory diseases and their management is another key driver. Public health campaigns and education on the importance of early diagnosis and proper treatment are increasing patient engagement. As patients in India become more informed about their conditions, they are seeking more effective and convenient solutions, such as combination therapies and smart inhalers. This shift toward patient-centric care will drive the adoption of advanced drug delivery systems, fueling market growth.

• Affordable pricing and insurance coverage: Affordable pricing and broader insurance coverage are crucial for market growth in India. High treatment costs often limit access to advanced pulmonary therapies, particularly for low-income patients. However, increasing insurance penetration and more affordable pricing models are expected to improve access to these therapies. With government support and insurance providers offering better coverage for respiratory treatments, more patients will be able to access high-quality pulmonary drug delivery systems, driving overall market expansion. The pulmonary drug delivery market in India is experiencing growth driven by the increasing prevalence of respiratory diseases, technological advancements in drug delivery devices, and enhanced government healthcare funding. While challenges such as high treatment costs and limited access in rural areas remain, the growing awareness and availability of affordable therapies are helping to address these issues. As the market continues to evolve, these drivers will contribute to improved patient care and the adoption of advanced pulmonary drug delivery technologies.

List of Pulmonary Drug Delivery Market in India Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, pulmonary drug delivery companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pulmonary drug delivery companies profiled in this report include:

• Company 1

• Company 2

• Company 3

• Company 4

• Company 5

Pulmonary Drug Delivery Market in India by Segment

The study includes a forecast for the pulmonary drug delivery market in India by application, end use, and distribution channel.

Pulmonary Drug Delivery Market in India by Application [Analysis by Value from 2019 to 2031]:

• Asthma

• Chronic Obstructive Pulmonary Disease

• Allergic Rhinitis

• Cystic Fibrosis

• Others

Pulmonary Drug Delivery Market in India by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics

• Home Care

Pulmonary Drug Delivery Market in India by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacies

• Retail Pharmacies

• E-Commerce

Features of the Pulmonary Drug Delivery Market in India

Market Size Estimates: Pulmonary drug delivery in India market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends and forecasts by various segments. Segmentation Analysis: Pulmonary drug delivery in India market size by application, end use, and distribution channel in terms of value ($B). Growth Opportunities: Analysis of growth opportunities in different application, end use, and distribution channel for the pulmonary drug delivery in India. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pulmonary drug delivery in India. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What are the major drivers influencing the growth of the pulmonary drug delivery market in India? Answer: The major drivers for this market are the rising prevalence of respiratory diseases, growing awareness of the benefits of pulmonary drug delivery, and the increasing demand for home-based healthcare services. Q2. What are the major segments for pulmonary drug delivery market in India? Answer: The future of the pulmonary drug delivery market in India looks promising with opportunities in the hospitals & clinic and home care markets. Q3. Which pulmonary drug delivery market segment in India will be the largest in future? Answer: Lucintel forecasts that chronic obstructive pulmonary disease (COPD) segment will remain the largest segment over the forecast period due to the increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease. Q4. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.